Hypoglycemia, dizziness, asthenia, headache, nausea, vomiting, gastrointestinal pain, diarrhea Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia anallergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions have been reported with sulfonylureas, including Glimepiride.

Glimepiride is contraindicated in patients with known hypersensitivity to the drug, diabetic ketoacidosis with or without coma. This condition should be treated with insulin.

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti inflammatory drugs and other drugs that are highly protein bound such as salicylates, sulfonamides, chloramphenicol, coumarins, probenacid, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When these drugs are administered to a patient receiving Glimepiride, the patient should be observed closely for hypoglycemia.

Overdosage of sulfonylureas, including Glimepiride, can produce hypoglycemia. Mild hypoglycemic symptoms without loss of consciousness of neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should be continued until the physician is assured that the patient is out of danger. Serious hypoglycemic reactions with coma, seizure or other neurological impairment occur infrequently but constitute medical emergencies requiring immediate hospitalization. If hypoglycemia is diagnosed orsuspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100mg/dl. Patient should be closely monitored for a minimum of 24-48 hours, because hypoglycemia may occur after apparent clinical recovery.

Store in a cool & dry place. Protect from light.